Skip to main navigation

Skip to content

Side Menu

About Us
Our Platform
Our Products
Our Programs
Patients and Physicians
Inside Seres
Open Positions
Investors and News
Contact Us

Press Releases

Seres' news, events and other information can be found throughout the pages below.

Investor Relations

Stock Information
News and Events
- Press Releases
- Events & Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Shareholder Services

Press Releases

Keyword Search

Year

Aug 01, 2023

Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023

Jul 14, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 21, 2023

Seres Therapeutics Named to TIME100 Most Influential Companies List

Jun 17, 2023

Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Jun 09, 2023

Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference

Jun 09, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 05, 2023

Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection

Jun 02, 2023

Seres Therapeutics to Present at Jefferies Healthcare Conference

May 30, 2023

Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™

May 10, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Next page
Last page

Shareholder Tools

RSS Feeds
E-mail Alerts
Print

© 2023 Seres Therapeutics.

Footer Left Menu

Privacy Policy
Terms of Use

Follow us on Linkedin
Follow us on Twitter
Follow us on Facebook